Nov 04, 2021 / 01:15PM GMT
Presentation (London-Based Investors)
Nov 04, 2021 / 01:15PM GMT
=====================
Corporate Participants
=====================
* Camilla Sylvest
Novo Nordisk A/S - Executive VP, Head of Commercial Strategy & Corporate Affairs and Member of the Management Board
* Karsten Munk Knudsen
Novo Nordisk A/S - Executive VP, CFO & Member of the Management Board
* Martin Holst Lange
Novo Nordisk A/S - Executive VP, Head of Development & Member of the Management Board
=====================
Conference Call Participants
=====================
* Jo Walton
Crédit Suisse AG, Research Division - MD
* Keyur Parekh
Goldman Sachs Group, Inc., Research Division - Equity Analyst
* Michael Leuchten
UBS Investment Bank, Research Division - Co-Head of Pharmaceuticals Research of Equity Research
* Peter Verdult
Citigroup Inc. Exchange Research - Research Analyst
* Peter James Welford
Jefferies LLC, Research Division - Senior Equity Analyst & European Pharmaceuticals
Novo Nordisk AS
(HAM:NOV)
€
40.67
+1.49 (+3.8%)
Market Cap: 180.41 Bil
Enterprise Value: 193.14 Bil
PE Ratio: 11.65
PB Ratio: 6.12
GF Score: 87/100 Q3 2021 Novo Nordisk A/S Earnings Presentation (London-Based Investors) Transcript
Nov 04, 2021 / 01:15PM GMT
Release Date Price:
€49.87
(+1.98%)
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot